Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

VOR

Insider Sentiment (TTM):

Last Purchase:2024-12-30Last Sale:2026-04-22Shares Purchased (TTM):0Shares Sold (TTM):3,906,175

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:40,267,793Shares Outstanding:43,011,544Institutional Ownership Pct.:93.62%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	108	170	396	160	191	50	82	53	76	45	31	45
Restricted Cash Equivalents Current	-	-	-	-	2	-	-	-	-	-	-	-
Marketable Securities Current	358	322	59	10	10	10	10	10	10	63	106	115
Prepaid Expense Current	6	6	1	1	2	5	4	4	4	4	3	4
Other Assets Current	3	3	2	1	0	0	0	0	0	1	0	1
Assets Current	475	501	458	172	205	65	97	67	90	112	141	164
Restricted Cash Equivalents Noncurrent	0	0	0	0	0	2	2	2	2	2	2	2
Property Plant And Equipment Net	1	1	1	0	0	6	7	7	8	9	10	11
Operating Lease Right Of Use Asset	3	3	3	3	0	34	35	36	38	39	40	41
Other Assets Noncurrent	2	2	2	0	0	2	2	3	3	5	5	4
Assets	481	507	464	176	205	109	143	116	142	167	198	223
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	1	5	1	1	4	2	1	2	2	1	1
Accrued Liabilities Current	20	15	20	18	58	9	13	9	8	7	11	10
Operating Lease Liability Current	0	0	0	0	0	4	4	4	4	4	4	4
Other Liabilities Current	-	-	-	-	-	0	0	0	0	0	0	0
Liabilities Current	25	16	25	19	59	17	19	14	14	13	16	15
Liabilities Noncurrent
Operating Lease Liability Noncurrent	3	3	3	3	0	27	28	29	30	31	32	33
Liabilities	681	657	628	2,402	1,711	43	46	43	44	44	47	48
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,236	1,223	989	650	557	556	554	499	497	494	491	489
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	0	0	0	0	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-1,435	-1,373	-1,153	-2,876	-2,063	-489	-457	-426	-399	-371	-340	-314
Stockholders Equity	-200	-150	-164	-2,225	-1,506	66	97	73	98	123	151	175
Liabilities And Stockholders Equity	481	507	464	176	205	109	143	116	142	167	198	223
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	800	800	800	800	800	400	400	400	400	400	400	400
Common Stock Shares Issued	54	54	39	9	6	6	6	3	3	3	3	0
Shares Outstanding	54	54	39	9	6	6	6	3	3	3	3	0
Stockholders Equity Note Stock Split Conversion Ra…	0	0	-	0	0	0	-	0	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-17.28%	29.42%	37.02%	-	-	-	-	-	-	-	-	-
2025	30.99%	1016.96%	1128.07%	18.07%	12.83%	-27.38%	-16.10%	19.38%	33.33%	-6.05%	-2.52%	-1.43%
2024	-25.41%	-44.75%	-46.85%	5.17%	-14.68%	-12.52%	-0.24%	52.28%	75.66%	-17.84%	-82.28%	-73.71%
2023	-	-	-	-	-	-	-3.52%	13.07%	17.59%	5.56%	-5.00%	-31.94%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	19.15	31.15	18.20	9.16	3.49	3.88	5.19	4.69	6.54	8.46	9.04	10.69
Quick Ratio	18.91	30.75	18.15	9.12	3.46	3.61	4.96	4.40	6.25	8.17	8.84	10.45
Working Capital	450.29M	484.70M	432.93M	153.65M	146.15M	48.12M	77.90M	52.95M	76.46M	98.60M	125.23M	149.05M
Leverage & Debt
Debt to Equity	-3.40	-4.37	-3.82	-1.08	-1.14	0.65	0.48	0.59	0.44	0.36	0.31	0.28
Debt Ratio	1.42	1.30	1.35	13.63	8.33	0.40	0.32	0.37	0.31	0.26	0.24	0.22
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	11.56	-20.53	-70.50	-366.60	-265.73	-19.00	-34.03	-32.85	-34.58	-35.35	-35.08	-34.17
Free Cash Flow Per Share TTM	-2.46	-3.51	-14.57	-16.99	-21.59	-24.50	-44.30	-44.46	-30.73	-31.63	-30.17	-28.37
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-137.72%	644.61%	495.29%	2,078.10%	1,309.41%	-1.36%	-0.81%	-2.64%	11.29%	22.95%	27.98%	33.64%
EPS Growth (1Y)	-104.35%	8.05%	107.17%	1,015.97%	668.42%	-46.24%	-3.00%	-3.87%	9.23%	19.76%	-96.23%	-96.24%
Valuation Metrics
P/E TTM	1.59	-0.87	-0.19	-0.13	-0.12	-0.76	-0.65	-0.43	-0.58	-1.34	-1.28	-1.24
P/B TTM	-4.99	-5.10	-0.79	-0.15	-0.13	1.36	0.79	0.66	0.70	1.31	1.00	0.82
Market Cap	999.75M	767.33M	129.12M	325.54M	202.94M	89.62M	76.27M	47.93M	68.30M	161.23M	151.18M	143.33M
Enterprise Value	891.89M	597.45M	133.72M	165.08M	12.37M	39.58M	-5.68M	-4.87M	-7.78M	116.27M	119.82M	98.30M
Calculated Values
Free Cash Flow TTM	-133.82M	-150.81M	-143.81M	-113.54M	-135.26M	-152.92M	-152.20M	-152.20M	-104.94M	-107.58M	-101.36M	-95.89M
Net Debt	-107.86M	-169.87M	4.60M	-160.46M	-190.57M	-50.05M	-81.95M	-52.80M	-76.08M	-44.96M	-31.36M	-45.03M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-22Sale

Owner: Shah, Rajeev M., Ra Capit…

Title: -

Shares: 165,150

Price/Share: $15.77

Value: $2,604,415.50

Shares Owned: 2,402,095

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-04-20Sale

Owner: Ra, Capital Management, L…

Title: -

Shares: 171,963

Price/Share: $15.77

Value: $2,711,856.51

Shares Owned: 2,567,245

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-04-15Sale

Owner: Ra, Capital Management, L…

Title: -

Shares: 53,644

Price/Share: $16.01

Value: $858,840.44

Shares Owned: 3,197,619

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-04-10Sale

Owner: Shah, Rajeev M., Ra Capit…

Title: -

Shares: 828

Price/Share: $15.75

Value: $13,041.00

Shares Owned: 3,935,608

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-04-06Sale

Owner: Kolchinsky, Peter, Ra Cap…

Title: -

Shares: 589,257

Price/Share: $17.44

Value: $10,276,642.08

Shares Owned: 4,555,741

Relationship: Director,TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-22	Shah, Rajeev M., Ra Capit…	Director,TenPercentOwner	-	Indirect	Sale	165,150	15.77	$2,604,415.50	2,402,095	4
2026-04-20	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Sale	171,963	15.77	$2,711,856.51	2,567,245	4
2026-04-15	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Sale	53,644	16.01	$858,840.44	3,197,619	4
2026-04-10	Shah, Rajeev M., Ra Capit…	Director,TenPercentOwner	-	Indirect	Sale	828	15.75	$13,041.00	3,935,608	4
2026-04-06	Kolchinsky, Peter, Ra Cap…	Director,TenPercentOwner	-	Indirect	Sale	589,257	17.44	$10,276,642.08	4,555,741	4
2025-10-30	Kolchinsky, Peter, Ra Cap…	Director,TenPercentOwner	-	Indirect	Sale	24,579	25.12	$617,424.48	779,652	4
2025-10-27	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Sale	90,941	28.12	$2,557,260.92	1,180,060	4
2025-10-21	Reprogrammed, Interchange…	TenPercentOwner	-	Direct	Sale	200	30.08	$6,016.00	1,166,909	4
2025-10-21	Ra, Capital Nexus Fund, L…	Director,TenPercentOwner	-	Indirect	Sale	25,027	28.11	$703,508.97	1,401,226	4
2025-10-17	Shah, Rajeev M., Ra Capit…	Director,TenPercentOwner	-	Indirect	Sale	260,859	30.13	$7,859,681.67	15,104	4
2025-10-16	Reprogrammed, Interchange…	TenPercentOwner	-	Direct	Sale	2,021	30.45	$61,539.45	1,204,442	4
2025-10-14	Reprogrammed, Interchange…	TenPercentOwner	-	Direct	Sale	33,668	30.32	$1,020,813.76	1,278,118	4
2025-10-09	Reprogrammed, Interchange…	TenPercentOwner	-	Direct	Sale	48,884	32.16	$1,572,109.44	1,374,775	4
2025-10-07	Reprogrammed, Interchange…	TenPercentOwner	-	Direct	Sale	27,624	33.84	$934,796.16	1,498,921	4
2025-10-03	Reprogrammed, Interchange…	TenPercentOwner	-	Direct	Sale	7,901	37.75	$298,262.75	1,597,308	4
2025-09-16	Hoffman, Reid, Reprogramm…	TenPercentOwner	-	Direct	Sale	447,278	1.54	$688,808.12	32,781,209	4
2025-09-15	Hoffman, Reid, Reprogramm…	TenPercentOwner	-	Direct	Sale	400,000	1.64	$656,000.00	33,228,487	4
2025-09-10	Hoffman, Reid, Reprogramm…	TenPercentOwner	-	Direct	Sale	350,000	1.82	$637,000.00	34,213,292	4
2025-09-05	Hoffman, Reid, Reprogramm…	TenPercentOwner	-	Direct	Sale	400,000	1.97	$788,000.00	35,476,939	4
2025-08-28	Hoffman, Reid, Reprogramm…	TenPercentOwner	-	Direct	Sale	806,351	2.01	$1,620,765.51	36,884,567	4
2025-08-26	Hoffman, Reid, Reprogramm…	TenPercentOwner	-	Direct	Sale	284,190	2.08	$591,115.20	38,302,565	4
2025-02-13	Attar, Eyal C.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,227	1.42	$3,162.34	126,625	4
2025-02-10	Attar, Eyal C.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,554	1.37	$3,498.98	128,852	4
2024-12-30	Hoffman, Reid, Reprogramm…	TenPercentOwner	-	Direct	Purchase	38,974,101	-	-	38,974,101	4
2024-12-27	Attar, Eyal C.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,334	1.25	$12,917.50	81,439	4
2024-06-03	Attar, Eyal C.	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	14,645	1.39	$20,356.55	96,063	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

93.62%

Inst. Shares: 40,267,793

Shares Outstanding: 43,011,544

2025-12-31

256.67%

Inst. Shares: 25,338,480

Shares Outstanding: 9,871,866

2025-09-30

56.17%

Inst. Shares: 3,753,197

Shares Outstanding: 6,681,794

2025-06-30

44.88%

Inst. Shares: 56,221,006

Shares Outstanding: 125,271,447

2025-03-31

Inst. Shares: 59,916,663

Shares Outstanding: 6,241,207

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	40,267,793	43,011,544	93.62%
2025-12-31	25,338,480	9,871,866	256.67%
2025-09-30	3,753,197	6,681,794	56.17%
2025-06-30	56,221,006	125,271,447	44.88%
2025-03-31	59,916,663	6,241,207	-
2024-12-31	60,709,074	3,435,533	-
2024-09-30	47,204,889	3,423,499	-
2024-06-30	53,843,466	68,299,170	78.83%
2024-03-31	58,063,559	68,030,966	85.35%
2023-12-31	56,692,795	67,191,973	84.37%
2023-09-30	57,224,179	67,607,713	84.64%
2023-06-30	57,564,084	67,033,150	85.87%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Vor Biopharma Inc. (VOR) — SEC Financial Statements & Analysis

Vor Biopharma Inc. (VOR) is a biological products, (no diagnostic substances) company. Vor Biopharma Inc. trades on Nasdaq as: VOR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vor Biopharma Inc. reported a Debt-to-Equity ratio of -3.40x, a Price-to-Book (P/B) ratio of -4.99x (TTM), at a market cap of $999.75M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: -3.40x
P/B TTM: -4.99x
Market Cap: $999.75M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Vor Biopharma Inc. in?

Vor Biopharma Inc. (VOR) operates in the Biological Products, (No Diagnostic Substances) industry.

What is VOR's market cap?

Vor Biopharma Inc. (VOR) has a market capitalization of $999.75M as of 2026-06-30.

What is VOR's P/E ratio?

Vor Biopharma Inc. (VOR)'s trailing twelve month P/E ratio is 1.59x as of 2026-06-30.

What exchange does VOR trade on?

Vor Biopharma Inc. (VOR) trades on the Nasdaq.